Core Viewpoint - The article highlights the successful clinical trial results of the NeoNova® mitral valve clip system, demonstrating its safety and efficacy in treating high-risk patients with degenerative mitral regurgitation [1][3][9]. Research Design - The NeoNova® pivotal trial is a prospective, single-arm, multi-center study conducted across 23 research centers in China, starting on April 26, 2022, and completing on March 21, 2024, with a total of 123 patients enrolled [4]. Efficacy and Safety Outcomes - The primary efficacy endpoint, defined as the treatment success rate at one year post-operation, was achieved with a rate of 92.68%, with 79.66% of patients showing MR ≤ 1+ and 96.62% showing MR ≤ 2+ [9]. - The safety profile indicated a major adverse event (MAE) rate of 9.76%, an all-cause mortality rate of 2.44%, and a cardiac mortality rate of 0.81% at one year post-operation [9]. Background on Mitral Regurgitation - Mitral regurgitation (MR) is a common heart valve disease in an aging population, with a 5-year mortality rate of 50% for untreated severe cases [10]. - In the U.S., the prevalence of MR is 1.7%, with approximately 4.1 million cases, of which 1.67 million require surgical intervention. In China, the number of patients with moderate to severe MR increased from 10 million in 2017 to 11.1 million in 2021, with a projected growth to 12.6 million by 2027 [12]. Treatment Landscape - The traditional treatment for MR involves surgical valve replacement, but only 2% of moderate to severe MR patients undergo surgery due to the high risks associated with open-heart procedures [13]. - A minimally invasive approach, Transcatheter Edge-to-Edge Repair (TEER), has gained traction, allowing for reduced trauma and quicker recovery [17]. About NeoNova® Mitral Valve Clip System - The NeoNova® system is designed for treating moderate to severe degenerative mitral regurgitation, particularly in patients who are at high surgical risk. It utilizes TEER to reduce regurgitation and improve cardiac function [20]. - The system received approval from the National Medical Products Administration (NMPA) in China on February 8, 2025 [21]. Company Overview - Jiangsu Zhenyi Medical Technology Co., Ltd. (Zhenyi Medical) was established in July 2019 and focuses on developing and manufacturing products for structural heart disease, including valves and devices for heart failure [23]. - The company has completed multiple rounds of financing, indicating strong investor confidence and support for its innovative solutions in cardiovascular disease treatment [28][31].

合作伙伴征集：2025全球手术机器人大会 2025年4月23日， 上海畅德医疗科技有限公司 （以下简称"畅德医疗"）宣布完成 超亿元A+轮融资。 本轮融 资由上实资本旗下的上海生物医药基金领投，兴证资本跟投，老股东君联资本、华杰高景持续加码跟投。资金 将主要用于公司创新产品的上市前临床与注册申报、核心产品的国际化注册以及海内外市场的拓展。 # 关于畅德医疗 畅德医疗成立于2021年，总部位于上海，是一家 专注于外周血管疾病治疗 的医疗器械研发商。公司致力于 为外周血管疾病提供完整解决方案，已构建覆盖 下肢动脉狭窄介入治疗、血栓管理、静脉疾病介入治疗及慢 性疾病管理 的产品矩阵。作为外周介入领域的新锐企业，畅德医疗凭借其创新的产品和技术，迅速在行业内 崭露头角，成为国产替代及中国创新出海背景下的重要力量。 产品与技术 畅德医疗的产品和技术具有显著的创新性和临床价值。公司自主研发的EF-Lumber ® 外周药物洗脱支架于 2025年3月获得国家药品监督管理局（NMPA）批准，进入创新医疗器械特别审查程序（"绿色通道"）。此 外，公司的首款产品 EF-Rhine ® 外周血管约束型球囊扩张导管 已于2023年12 ...

报名：首届全球骨科大会 | 参会须知 报名：首届全球心血管大会 | 重磅亮点 合作伙伴征集：2025全球手术机器人大会 2025年4月22日， 爱博 医疗 发布了2024年年报。 公司2025年一季度实现收入 3.57亿 元（同比+15.07%），归母净利润0.93亿元（同比-10.05%），扣非归 母净利润0.86亿元（同比-12.83%）。 2024 年 5 月起，人工晶状体国家集采政策陆续落地实施，受此影 响，终端医院手术量减少，手术价格下降，人工晶状体出厂价格也出现下滑，这直接导致了公司2025 年第一 季度手术业务收入和毛利的增速放缓。在近视防控领域，市场竞争日益激烈，竞品不断增多，公司角膜塑形镜 出厂价格因此略有下调，对公司业绩增长的贡献也有所减弱。此外，公司的隐形眼镜业务板块尚处于培育阶 段，目前对公司利润的贡献较小，未来还有较大的待提升空间。 2024年拆分 # 关于爱博 医疗 爱博诺德（北京）医疗科技股份有限公司成立于2010年4月21日，总部位于北京中关村国家自主创新示范 区。公司是一家专注于 眼科医疗器械研发、生产和销售 的高新技术企业，于2020年在科创板上市（股票代 码：688050 ...

报名：首届全球骨科大会 | 参会须知 报名：首届全球心血管大会 | 重磅亮点 合作伙伴征集：2025全球手术机器人大会 2025年4月22日， 惠泰医疗 发布了2024年年报。 # 财务与市场表现 骨未来 | 智汇骨 | 思宇MedTech 首届全球骨科大会 Global Orthopedics Conference 主办单位:骨未来、智汇骨、思宇MedTech 协办单位:中关村联新生物医药产业联盟 支持单位:北京中关村科学城创新发展有限公司 北京中关村创业大街科技服务有限公司 启迪之星 中关村科学城CGT产业孵化中心 中国 北京 2025年4月24日 心未来 | 思宇MedTech 24年实现营收 20.66亿 元（+25.2%）；归母净利润 6.73亿 元（+26.1%） ；扣非归母净利润6.43亿元 （+37.3%）。经计算，24年Q4实现营收5.41亿元（+23.9%）；归母净利润1.45亿元（+11.0%）；扣非归 母净利润1.35亿元（+24.69%）。25年Q1公司实现营收5.64亿元 (+23.9%)，归母净利润1.83亿元 (+30.7%)，扣非归母净利润1.81亿元 (+32.2%)。24 ...

Financial and Market Performance - In 2024, the company achieved revenue of 2.066 billion yuan (+25.2%) and a net profit attributable to shareholders of 673 million yuan (+26.1%), with a non-recurring net profit of 643 million yuan (+37.3%) [2] - For Q4 2024, the company reported revenue of 541 million yuan (+23.9%) and a net profit of 145 million yuan (+11.0%), with a non-recurring net profit of 135 million yuan (+24.69%) [2] - In Q1 2025, the company generated revenue of 564 million yuan (+23.9%) and a net profit of 183 million yuan (+30.7%), with a non-recurring net profit of 181 million yuan (+32.2%) [2] - The growth in profits for 2024 and Q1 2025 was driven by increased sales volume, enhanced product profitability, and cost control measures [2] Business Segments - In 2024, the electrophysiology business generated revenue of 440 million yuan (+19.7%), while the coronary access segment achieved 1.054 billion yuan (+33.3%), and peripheral intervention revenue was 351 million yuan (+37.1%) [2] - Non-vascular intervention revenue reached 39 million yuan, showing a significant increase of 135.1%, while OEM revenue was 165 million yuan, a decrease of 21.7% [2] - Domestic business overall achieved 1.769 billion yuan (+25.7%), while overseas business revenue was 280 million yuan (+19.6%) [2] Product and Market Expansion - In 2024, the company added over 200 new hospitals for electrophysiology products, covering more than 1,360 hospitals, and completed over 15,000 three-dimensional electrophysiology surgeries, a 50% increase year-on-year [3] - The company maintains a leading market share in the adjustable bend ten-electrode coronary sinus catheter, with an annual usage exceeding 100,000 units [3] - In 2025, the company plans to complete clinical follow-ups for PFA net basket consumables and the ICE project registration, while advancing clinical projects for abdominal aortic stents and coronary peripheral shock wave balloons [3] Profitability Metrics - The gross margin for 2024 was 72.3% (+1.1 percentage points year-on-year), and the net profit margin was 32.6% (+0.2 percentage points year-on-year) [3] - For Q4 2024, the gross margin was 71.3% (+0.3 percentage points year-on-year), while the net profit margin was 26.8% (-3.1 percentage points year-on-year) [3] - In Q1 2025, the gross margin improved to 73.1% (+2.4 percentage points year-on-year), and the net profit margin was 32.5% (+1.7 percentage points year-on-year) [3] Dividend Policy - The company plans to distribute a cash dividend of 17.50 yuan (including tax) for every 10 shares to all shareholders, which accounts for 25.24% of the net profit attributable to shareholders for 2024 [3] Company Overview - Shenzhen Huitai Medical Devices Co., Ltd. is a high-tech enterprise established in 2002, focusing on the research, development, production, and sales of electrophysiology and interventional medical devices [4] - The company is headquartered in Shenzhen and has developed a product line primarily centered on coronary access and cardiac electrophysiology medical devices, with a focus on peripheral vascular and non-vascular interventional medical devices [4] - Huitai Medical emphasizes research and innovation, holding numerous domestic and international medical device registrations and certifications, with products sold in various countries and regions worldwide [4]

报名：首届全球骨科大会 | 参会须知 报名：首届全球心血管大会 | 重磅亮点 合作伙伴征集：2025全球手术机器人大会 2025年4月23日， 安杰思 发布了2024年年报。 # 公司业务核心驱动力 # 关于安杰思 杭州安杰思医学科技股份有限公司是一家专注于内镜微创诊疗器械研发、生产和销售的高新技术企业，成立于 2010年12月，2023年5月成功上市。公司位于浙江省杭州市余杭区，其产品涵盖止血闭合类、EMR/ESD 类、活检类、ERCP类及仪器类等多个品类，广泛应用于 消化内镜、呼吸内镜、耳鼻喉内镜、泌尿内镜和妇 科内镜 等五大领域。安杰思高度重视技术创新，截至2024年末，累计申请专利367项，其中发明专利239 项，有效授权专利100项，48%以上专利已应用于产品，为公司带来了显著的市场竞争力。 # 财务与市场表现 主要财务数据 ： 2024年公司营业收入为 6.37亿 元，同比 增长25.14% ； 归属于上市公司股东的净利 润为2.93亿元，同比增长35.06%；归属于上市公司股东的扣除非经常性损益的净利润为2.73亿元，同比 增长28.62%；经营活动产生的现金流量净额为3.16亿元，同比增长42 ...

报名：首届全球骨科大会 | 参会须知 报名：首届全球心血管大会 | 重磅亮点 合作伙伴征集：2025全球手术机器人大会 2025年4月21日， 脉冲场导管消融领域的创新公司 Field Medical 宣布成功完成了 4000万美元（合约 2.9亿人民币） 的A轮融资。参与本轮融资的包括行业战略投资者、风险投资公司等，多位种子轮投资者 再次投资，凸显了对公司技术的强烈信心。 # 融资详情 这笔资金将支持 完成两项初步研究： 针对心室性心动过速（VT）的VCAS研究和针对房颤（AF）的 Field PULSE研究。 同时还将继续推进Field公司商业脉冲场消融（PFA）系统的开发以及 扩大运营规模，为公司即将开展的 以VT为重点的 关键性试验VERITAS 做好准备。 Field Medical的创始人兼首席执行官Steven Mickelsen博士表示，"这笔融资是我们重新定义电生理学 家对待消融疗法方式的关键一步， 我们正在加速FieldForce ™ 消融系统的开发，努力扩大 新一代脉冲场消融（PFA）解决方案在心脏消融领域的适用范围。" Field Force是Field Medical的核心产品，是 ...

Financial and Market Performance - In 2024, the company's operating revenue reached 637 million yuan, representing a year-on-year growth of 25.14% [2] - The net profit attributable to shareholders was 293 million yuan, an increase of 35.06% year-on-year [2] - The net profit after deducting non-recurring gains and losses was 273 million yuan, up 28.62% year-on-year [2] - The net cash flow from operating activities was 316 million yuan, reflecting a growth of 42.61% [2] Core Business Drivers - The company focuses on the research, development, production, and sales of minimally invasive diagnostic and therapeutic instruments, with a wide range of products used in various endoscopic fields [1] - The aging population, increased health awareness, and improved medical insurance levels are driving demand for endoscopic minimally invasive diagnostic and therapeutic instruments, providing significant market opportunities for the company [2] Company Overview - Hangzhou Anjiasi Medical Technology Co., Ltd. was established in December 2010 and successfully went public in May 2023 [1] - The company has applied for a total of 367 patents, with 239 being invention patents, and over 48% of these patents have been applied to products, enhancing its market competitiveness [1][2] Profitability - The gross profit margin for 2024 was 72.11%, an increase of 1.24 percentage points year-on-year [2] - The net profit margin was 46.09%, up 3.38 percentage points compared to the previous year [2] Expense Situation - The company's period expenses for 2024 amounted to 132 million yuan, an increase of 23.48 million yuan year-on-year [2] - The period expense ratio was 20.81%, a decrease of 0.61 percentage points year-on-year [2] - Research and development expenses increased by 43.53% year-on-year, indicating a strong focus on innovation [2] Brand and Customer Resources - The company has established a strong brand image and customer resources through years of market accumulation, forming long-term stable partnerships with numerous medical institutions [2]

合作伙伴征集：2025全球手术机器人大会 2025年4月21日， 港通医疗 发布了2024年年报。 # 财务与市场表现 # 主营业务与商业模式 港通医疗的业务主要分为 医用气体装备及系统、医用洁净装备及系统和医疗设备及其他产品销售 。2024 年，医用气体装备及系统业务收入2.22亿元，同比减少46.50%；医用洁净装备及系统业务收入4.93亿元，同 比增长32.06%；医疗设备及其他产品销售收入2266.39万元，同比下降43.48%。公司通过与国有总承包方 合作获取订单，但该模式压缩了毛利空间。 # 综合分析 2024年公司营业收入和净利润均出现下滑，主要原因是市场竞争加剧和项目进度不及预期。公司从国有总承 包方获取订单的比例逐渐增加，导致毛利空间被压缩。 尽管部分业务收入下滑，但医用洁净装备及系统业务仍保持增长，显示出一定的市场潜力。此外，公司计划通 过加强成本控制和缩短回款周期来提升整体经营能力。 # 关于 港通医疗 报名：首届全球骨科大会 | 议程更新 报名：首届全球心血管大会 | 重磅亮点 产品和技术 港通医疗的主要产品包括 医用中心供氧系统、医用中心吸引系统、医用空气集中供应系统等医用气体装备及 ...